(3-endo)-benzyl3-(hydroxymethyl)-8-azabicyclo[3.2.1]octane-8-carboxylate
![]() |
- $150 - $564
- Product name: (3-endo)-benzyl3-(hydroxymethyl)-8-azabicyclo[3.2.1]octane-8-carboxylate
- CAS: 1067230-68-5
- MF: C16H21NO3
- MW: 275.34
- EINECS:
- MDL Number:MFCD28347830
- Synonyms:(3-endo)-benzyl3-(hydroxymethyl)-8-azabicyclo[3.2.1]octane-8-carboxylate;(3-EXO)-BENZYL3-(HYDROXYMETHYL)-8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXYLATE;Benzyl endo-3-(hydroxymethyl)-8-azabicyclo[3.2.1]octane-8-carboxylate;8-Azabicyclo[3.2.1]octane-8-carboxylic acid, 3-(hydroxymethyl)-, phenylmethyl ester, (3-endo)-;endo-8-Cbz-8-azabicyclo[3.2.1]octane-3-methanol
3 prices
Selected condition:
Brand
- Crysdot
- TRC
Package
- 50mg
- 100mg
- 1g
- ManufacturerCrysdot
- Product numberCD11357173
- Product descriptionBenzyl3-(hydroxymethyl)-8-azabicyclo[3.2.1]octane-8-carboxylate 95+%
- Packaging1g
- Price$564
- Updated2021-12-16
- Buy
- ManufacturerTRC
- Product numberB278840
- Product descriptionBenzyl3-(Hydroxymethyl)-8-azabicyclo[3.2.1]octane-8-carboxylate
- Packaging50mg
- Price$150
- Updated2021-12-16
- Buy
- ManufacturerTRC
- Product numberB278840
- Product descriptionBenzyl3-(Hydroxymethyl)-8-azabicyclo[3.2.1]octane-8-carboxylate
- Packaging100mg
- Price$230
- Updated2021-12-16
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
Crysdot | CD11357173 | Benzyl3-(hydroxymethyl)-8-azabicyclo[3.2.1]octane-8-carboxylate 95+% | 1g | $564 | 2021-12-16 | Buy |
TRC | B278840 | Benzyl3-(Hydroxymethyl)-8-azabicyclo[3.2.1]octane-8-carboxylate | 50mg | $150 | 2021-12-16 | Buy |
TRC | B278840 | Benzyl3-(Hydroxymethyl)-8-azabicyclo[3.2.1]octane-8-carboxylate | 100mg | $230 | 2021-12-16 | Buy |
Properties
Boiling point :427.2±28.0 °C(Predicted)
Density :1.192±0.06 g/cm3(Predicted)
pka :14.93±0.10(Predicted)
Density :1.192±0.06 g/cm3(Predicted)
pka :14.93±0.10(Predicted)
Safety Information
Symbol(GHS): | ||||||||
---|---|---|---|---|---|---|---|---|
Signal word: | ||||||||
Hazard statements: |
|
|||||||
Precautionary statements: |
|